BioNTech SE
BNTXNext catalyst
BNT162b2
SARS-CoV-2 Infection
Get an email about BNTX's next catalysts
Track BioNTech (BNTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 7 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
8 upcoming, 2 past
BNT162b2 Phase 3 Est. Readout
Estimated primary completion for BNT162b2 trial (NCT07798648) in COVID-19 Vaccines. Topline data typically follows completion by weeks to months.
SourcePM8002 Phase 2 Est. Readout
Estimated primary completion for PM8002 trial (NCT07133750) in CRC (Colorectal Cancer). Topline data typically follows completion by weeks to months.
SourceBNT166a Phase 2 Est. Readout
Estimated primary completion for BNT166a trial (NCT07379580) in Mpox (Monkeypox). Topline data typically follows completion by weeks to months.
SourceBNT327 Dose Level 1 (DL1) Phase 2 Est. Readout
Estimated primary completion for BNT327 Dose Level 1 (DL1) trial (NCT06449209) in Extensive-stage Small-cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceDB-1305/BNT325 Phase 2 Est. Readout
Estimated primary completion for DB-1305/BNT325 trial (NCT05438329) in Advanced Solid Tumor. Topline data typically follows completion by weeks to months.
SourceDB-1303/BNT323 Phase 2 Est. Readout
Estimated primary completion for DB-1303/BNT323 trial (NCT05150691) in HER2-positive Advanced Solid Tumor. Topline data typically follows completion by weeks to months.
SourceGotistobart Phase 3 Est. Readout (PRESERVE-003)
Estimated primary completion for Gotistobart trial (NCT05671510) in Non Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceBNT3212 Phase 2 Est. Readout
Primary completion for BNT3212 trial (NCT07147348) in Advanced Solid Tumor
SourceHow BNTX's past catalysts played out
Market Overview
Stock performance and key metrics
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
WebsitePumitamig
Extensive-stage Small-cell Lung Cancer
BNT162b2
SARS-CoV-2 Infection
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
BNT162b1
SARS-CoV-2 Infection
BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b2 (Omi XBB.1.5)
SARS-CoV-2 Infection
BNT162b5 Bivalent (WT/OMI BA.2)
SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine
SARS-CoV-2 Infection
Influenza and COVID-19 Combination A
Influenza
BNT162b2 (2025/2026 formulation)
COVID-19
BNT162b2.B.1.351
SARS-CoV-2 Infection
BNT162b2 (Omi LP.8.1)
COVID-19
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
SARS-CoV-2 Virus
Investigational Influenza Vaccine
Influenza,Human
Combination (Bivalent) BNT162b2 and BNT162b2 OMI
SARS-CoV-2 Infection
Combination BNT162b2 and BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b2 Vaccine
COVID-19
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
COVID-19
BNT324
Advanced Lung Cancer
Prednisone/prednisolone
Metastatic Castration-resistant Prostate Cancer
Gotistobart
Non Small Cell Lung Cancer
DB-1303/BNT323
HER2-positive Breast Cancer
BNT323/DB-1303
Endometrial Cancer
BNT162b5 Bivalent (Original/OMI BA.4/BA.5)
SARS-CoV-2 Infection
BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
SARS-CoV-2 Infection
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
SARS-CoV-2 Virus
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
SARS-CoV-2 Virus
BNT162b2 (Omi KP.2)
SARS-CoV-2 Infection
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
SARS-CoV-2 Virus
BNT162b2 Bivalent (WT/OMI BA.1)
SARS-CoV-2 Infection
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)
SARS-CoV-2 Infection
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose
SARS-CoV-2 Virus
BNT162b2SA
SARS-CoV-2 Infection
Carboplatin (or cisplatin if carboplatin is not tolerated)
Extensive-stage Small-cell Lung Cancer
Influenza and COVID-19 Combination B
Influenza
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose
SARS-CoV-2 Virus
BNT162b2 (Omi JN.1)
SARS-CoV-2 Infection
Capox
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
BNT162b7 Monovalent (OMI BA.4/BA.5)
SARS-CoV-2 Infection
BNT162b6 Bivalent (Original/OMI BA.4/BA.5)
SARS-CoV-2 Infection
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
SARS-CoV-2 Virus
qIRV (22/23)
Influenza, Human
QIV
Influenza, Human
tIRV
Influenza, Human
BNT165c
Malaria
Nab-placlitaxel
Locally Advanced Breast Cancer
BNT317 DL2
Advanced Solid Tumor
Lopinavir and Ritonavir Tablets
Advanced Solid Tumors
SoC chemotherapy 1
Advanced Solid Tumor
BNT165d
Malaria
BNT3214
Advanced Solid Tumor Cancer
BNT327 Optimized Dose
Locally Advanced Breast Cancer
Obrixtamig
Extensive-stage Small Cell Lung Carcinoma
BNT327 Dose Level 1 (DL1)
Extensive-stage Small-cell Lung Cancer
BNT317 DL6
Advanced Solid Tumor
DB-1311
Advanced Solid Tumors
BNT317 DL1
Advanced Solid Tumor
DB-1305/BNT325
Advanced Solid Tumor
PM8002
CRC (Colorectal Cancer)
BNT317 DL5
Advanced Solid Tumor
BNT329
Advanced Solid Cancers
BNT326
Advanced Solid Tumor
BNT162b3
Covid-19
BNT111
Melanoma Stage III
Pertuzumab Injection
HER2-positive Advanced Solid Tumor
Autogene cevumeran
Advanced Melanoma
BNT314
Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)
Influenza, Human
BNT162b2s01
COVID-19
DB-1311/BNT324
Solid Tumors
BNT327
Non-small Cell Lung Cancer
BNT142
Solid Tumor
BNT327 Equivalent Q3W Dose
Locally Advanced Breast Cancer
BNT3212
Advanced Solid Tumor
Monovalent BNT162b2 (B.1.1.529.1)
SARS-CoV-2 Infection
BNT317 DL3
Advanced Solid Tumor
SoC chemotherapy 2
Advanced Solid Tumor
RO7198457 intravenous (IV)
Colorectal Cancer Stage II
BNT317 selected DLA
Advanced Solid Tumor
BNT327 Dose Level 2 (DL2)
Extensive-stage Small-cell Lung Cancer
BNT166a
Monkeypox
BNT323
Locally Advanced Breast Cancer
Investigational COVID-19 Vaccine
Influenza
Monovalent BNT162b2 (B.1.1.7)
SARS-CoV-2 Infection
BNT165e
Malaria
COVID-19 Vaccine
Influenza,Human
Monovalent BNT162b2 (B.1.617.2)
SARS-CoV-2 Infection
BNT162a1
Infections, Respiratory
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
SARS-CoV-2 Infection
BNT164a1
Tuberculosis
BNT327 Dose Level 1 (DL2)
Locally Advanced Breast Cancer
BNT317 DL4
Advanced Solid Tumor
bIRV
Influenza, Human
Chemotherapy Regimen 3
CRC (Colorectal Cancer)
CA19-9-targeting monoclonal antibody
Advanced Solid Cancers
BNT162c2
Infections, Respiratory
Chemotherapy Regimen 2
CRC (Colorectal Cancer)
BNT317 selected DLB
Advanced Solid Tumor
Chemotherapy Regimen 1
CRC (Colorectal Cancer)
BNT164b1
Tuberculosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma | - | - |
BNT162b1 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection | - | - |
Influenza and COVID-19 Combination A | Phase 3 | Influenza | - | - |
BNT162b2 (2025/2026 formulation) | Phase 3 | COVID-19 | - | - |
BNT162b2.B.1.351 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi LP.8.1) | Phase 3 | COVID-19 | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
Investigational Influenza Vaccine | Phase 3 | Influenza,Human | - | - |
Combination (Bivalent) BNT162b2 and BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
Combination BNT162b2 and BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 Vaccine | Phase 3 | COVID-19 | - | - |
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | Phase 3 | COVID-19 | - | - |
BNT324 | Phase 3 | Advanced Lung Cancer | - | - |
Prednisone/prednisolone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Gotistobart | Phase 3 | Non Small Cell Lung Cancer | - | - |
DB-1303/BNT323 | Phase 3 | HER2-positive Breast Cancer | - | - |
BNT323/DB-1303 | Phase 3 | Endometrial Cancer | - | - |
BNT162b5 Bivalent (Original/OMI BA.4/BA.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
BNT162b2 (Omi KP.2) | Phase 3 | SARS-CoV-2 Infection | - | - |
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
BNT162b2 Bivalent (WT/OMI BA.1) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b7 Bivalent (Original/OMI BA.4/BA.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
BNT162b2SA | Phase 3 | SARS-CoV-2 Infection | - | - |
Carboplatin (or cisplatin if carboplatin is not tolerated) | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
Influenza and COVID-19 Combination B | Phase 3 | Influenza | - | - |
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
BNT162b2 (Omi JN.1) | Phase 3 | SARS-CoV-2 Infection | - | - |
Capox | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
BNT162b7 Monovalent (OMI BA.4/BA.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b6 Bivalent (Original/OMI BA.4/BA.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
qIRV (22/23) | Phase 2 | Influenza, Human | - | - |
QIV | Phase 2 | Influenza, Human | - | - |
tIRV | Phase 2 | Influenza, Human | - | - |
BNT165c | Phase 2 | Malaria | - | - |
Nab-placlitaxel | Phase 2 | Locally Advanced Breast Cancer | - | - |
BNT317 DL2 | Phase 2 | Advanced Solid Tumor | - | - |
Lopinavir and Ritonavir Tablets | Phase 2 | Advanced Solid Tumors | - | - |
SoC chemotherapy 1 | Phase 2 | Advanced Solid Tumor | - | - |
BNT165d | Phase 2 | Malaria | - | - |
BNT3214 | Phase 2 | Advanced Solid Tumor Cancer | - | - |
BNT327 Optimized Dose | Phase 2 | Locally Advanced Breast Cancer | - | - |
Obrixtamig | Phase 2 | Extensive-stage Small Cell Lung Carcinoma | - | - |
BNT327 Dose Level 1 (DL1) | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
BNT317 DL6 | Phase 2 | Advanced Solid Tumor | - | - |
DB-1311 | Phase 2 | Advanced Solid Tumors | - | - |
BNT317 DL1 | Phase 2 | Advanced Solid Tumor | - | - |
DB-1305/BNT325 | Phase 2 | Advanced Solid Tumor | - | - |
PM8002 | Phase 2 | CRC (Colorectal Cancer) | - | - |
BNT317 DL5 | Phase 2 | Advanced Solid Tumor | - | - |
BNT329 | Phase 2 | Advanced Solid Cancers | - | - |
BNT326 | Phase 2 | Advanced Solid Tumor | - | - |
BNT162b3 | Phase 2 | Covid-19 | - | - |
BNT111 | Phase 2 | Melanoma Stage III | - | - |
Pertuzumab Injection | Phase 2 | HER2-positive Advanced Solid Tumor | - | - |
Autogene cevumeran | Phase 2 | Advanced Melanoma | - | - |
BNT314 | Phase 2 | Metastatic Colorectal Cancer | - | - |
bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human | - | - |
BNT162b2s01 | Phase 2 | COVID-19 | - | - |
DB-1311/BNT324 | Phase 2 | Solid Tumors | - | - |
BNT327 | Phase 2 | Non-small Cell Lung Cancer | - | - |
BNT142 | Phase 2 | Solid Tumor | - | - |
BNT327 Equivalent Q3W Dose | Phase 2 | Locally Advanced Breast Cancer | - | - |
BNT3212 | Phase 2 | Advanced Solid Tumor | - | - |
Monovalent BNT162b2 (B.1.1.529.1) | Phase 2 | SARS-CoV-2 Infection | - | - |
BNT317 DL3 | Phase 2 | Advanced Solid Tumor | - | - |
SoC chemotherapy 2 | Phase 2 | Advanced Solid Tumor | - | - |
RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II | - | - |
BNT317 selected DLA | Phase 2 | Advanced Solid Tumor | - | - |
BNT327 Dose Level 2 (DL2) | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
BNT166a | Phase 2 | Monkeypox | - | - |
BNT323 | Phase 2 | Locally Advanced Breast Cancer | - | - |
Investigational COVID-19 Vaccine | Phase 2 | Influenza | - | - |
Monovalent BNT162b2 (B.1.1.7) | Phase 2 | SARS-CoV-2 Infection | - | - |
BNT165e | Phase 2 | Malaria | - | - |
COVID-19 Vaccine | Phase 2 | Influenza,Human | - | - |
Monovalent BNT162b2 (B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - | - |
BNT162a1 | Phase 2 | Infections, Respiratory | - | - |
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - | - |
BNT164a1 | Phase 2 | Tuberculosis | - | - |
BNT327 Dose Level 1 (DL2) | Phase 2 | Locally Advanced Breast Cancer | - | - |
BNT317 DL4 | Phase 2 | Advanced Solid Tumor | - | - |
bIRV | Phase 2 | Influenza, Human | - | - |
Chemotherapy Regimen 3 | Phase 2 | CRC (Colorectal Cancer) | - | - |
CA19-9-targeting monoclonal antibody | Phase 2 | Advanced Solid Cancers | - | - |
BNT162c2 | Phase 2 | Infections, Respiratory | - | - |
Chemotherapy Regimen 2 | Phase 2 | CRC (Colorectal Cancer) | - | - |
BNT317 selected DLB | Phase 2 | Advanced Solid Tumor | - | - |
Chemotherapy Regimen 1 | Phase 2 | CRC (Colorectal Cancer) | - | - |
BNT164b1 | Phase 2 | Tuberculosis | - | - |
SARS-CoV-2 Infection
8 drugs in this indication
COVID-19
4 drugs in this indication
cancer
3 drugs in this indication
Influenza
2 drugs in this indication
Influenza,Human
2 drugs in this indication
Locally Advanced Breast Cancer
2 drugs in this indication
Advanced Solid Tumor
2 drugs in this indication
oncology/cancer
1 drug in this indication
Advanced Lung Cancer
1 drug in this indication
Colorectal Cancer Stage II
1 drug in this indication
SARS-CoV-2 Virus
1 drug in this indication
Non-small Cell Lung Cancer
1 drug in this indication
Tuberculosis
1 drug in this indication
Malaria
1 drug in this indication
Infections, Respiratory
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Solid Tumor
1 drug in this indication
Advanced Solid Cancers
1 drug in this indication
Monkeypox
1 drug in this indication
Extensive-stage Small-cell Lung Cancer
1 drug in this indication
respiratory syncytial virus
1 drug in this indication
Melanoma Stage III
1 drug in this indication
colorectal cancer
1 drug in this indication
SARS-CoV-2 Infection, COVID-19
1 drug in this indication
Unresectable Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BioNTech SE's drug pipeline?→
CatalystAlert tracks 100 drug candidates in BioNTech SE's (BNTX) pipeline across Phase 3, Phase 2. Its lead program is BNT162b2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioNTech SE's next FDA catalyst?→
BioNTech SE's (BNTX) next tracked catalyst is a Phase 3 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BNTX biotech catalysts?→
Add BNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioNTech SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
